anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: Cardiac implantable electronic device (CIED) infections are a burden to hospitals and costly for healthcare systems. Chronic kidney disease (CKD) increases the risk of CIED infections, but its differential impact on healthcare utilization, costs, and outcomes is not known.
METHODS AND RESULTS: This retrospective analysis used de-identified Medicare Fee-for-Service claims to identify patients implanted with a CIED from July 2016 to December 2020. Outcomes were defined as hospital days and costs within 12 months post-implant, post-infection CKD progression, and mortality. Generalized linear models were used to calculate results by CKD and infection status while controlling for other comorbidities, with differences between cohorts representing the incremental effect associated with CKD. A total of 584 543 patients had a CIED implant, of which 26% had CKD and 1.4% had a device infection. The average total days in hospital for infected patients was 23.5 days with CKD vs. 14.5 days (P < 0.001) without. The average cost of infection was $121 756 with CKD vs. $55 366 without (P < 0.001), leading to an incremental cost associated with CKD of $66 390. Infected patients with CKD were more likely to have septicaemia or severe sepsis than those without CKD (11.0 vs. 4.6%, P < 0.001). After infection, CKD patients were more likely to experience CKD progression (hazard ratio 1.26, P < 0.001) and mortality (hazard ratio 1.89, P < 0.001).
CONCLUSION: Cardiac implantable electronic device infection in patients with CKD was associated with more healthcare utilization, higher cost, greater disease progression, and greater mortality compared to patients without CKD.
OBJECTIVE: This research aims to investigate the impact of individualized antiplatelet therapy guided by thromboelastography with platelet mapping (TEG-PM) on the clinical outcomes of patients with non-cardiogenic ischemic stroke.
METHODS: Among a total of 1264 patients, 684 individuals diagnosed with non-cardiogenic ischemic stroke underwent TEG-PM testing. Based on the adjustment of antiplatelet medication, these patients were divided into individual and control groups. Within the individual group, in accordance with the TEG-PM test results, a Maximum amplitude (MA) value greater than 47mm was defined as high residual platelet reactivity (HRPR), while an MA value less than 31mm was defined as low residual platelet reactivity (LRPR). Patients with arachidonic acid (AA) less than 50% and adenosine diphosphate (ADP) less than 30% were classified as aspirin-resistant or clopidogrel-resistant. Treatment strategies for antiplatelet medication were subsequently adjusted accordingly, encompassing increment, decrement, or replacement of drugs. Meanwhile, the control group maintained their original medication regimen without alterations.
RESULTS: The individual group included 487 patients, while the control group had 197. In the individual group, approximately 175 patients (35.9%) were treated with increased medication dosages, 89 patients (18.3%) with reduced dosages, and 223 patients (45.8%) switched medications. The results showed that the incidence rate of ischemic events in the individual group was lower than that of the control group (5.54% vs. 12.6%, P = 0.001), but no significant difference was observed in bleeding events. Cox regression analysis revealed age (hazard ratio, 1.043; 95% CI, 1.01-1.078; P = 0.011) and coronary heart disease (hazard ratio, 1.902; 95% CI, 1.147-3.153; P = 0.013) as significant risk factors for adverse events.
CONCLUSION: Individualized antiplatelet therapy based on TEG-PM results can reduce the risk of ischemic events in patients with non-cardiogenic ischemic stroke without increasing the risk of bleeding events or mortality. Advanced age and coronary heart disease were identified as risk factors affecting the outcomes of individualized antiplatelet therapy.
PURPOSE:To obtain a remedy effective for thrombocytopenia induced by hematopoietic injury, comprising a human monocyte-macropharge colony stimulating factor as an active ingredient. CONSTITUTION:A remedy for thrombocytopenia containing a human monocyte- macropharge colony stimulating factor having the following properties of physical chemistry. Molecular weight:a homogeneous dimer consisting of the same two subunits, having 70,000-90,000 dalton molecular weight measured by sodium dodecyl sulfate.acrylamide gel electrophoresis and subunit having 35,000-450,000 dalton molecular weight. Amino acid composition of subunit:having 214-238 amino acid sequence and 122nd Asn having N-glycoside bond site of Asn-X-Thr- Ser. Isoelectric point:3.1-3.7. Constituent monosaccharide of saccharide chain: mannose, galactose, N-acetylglucosamine, N-acetylgalactosamine and N- acetylneuraminic acid. Thermal stability:not losing biological activity by heating at 60+ or -0.5 deg.C for 60 minutes.
<P>PROBLEM TO BE SOLVED: To advertise medicine, medical material, and examination to a doctor at a pinpoint timing.  <P>SOLUTION: A computer system having the following three functions has been invented. First, there is provided the computer system in which, by efficiently employing the characteristic of an electronic medical record that a doctor directly inputs the medical records therein, as soon as the doctor starts a treatment, in accordance with the input disease name, an advertisement frame is displayed regarding medicine, medical material, and examination on a screen of the electronic medical record. Second, there is provided the computer system which automatically takes a step not to display a medicine in the advertisement frame even when the advertisement is reserved, when a medicine is incompatible with a disease name or a medicine. Third, there is provided the computer system in which, when a certain period of time passes with no input, until a next input event of any kind is generated, the electronic medical record screen is switched to display an advertisement of medicine, medical material, and examination which are not conscious of a disease name of a specified patient.  <P>COPYRIGHT: (C)2007,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide a new therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine).  <P>SOLUTION: The acadesine (also known as AICA riboside or AICAR) does not inhibit apoptosis in lymphocytes but it induces apoptosis in B cells from patients with B-cell lymphoproliferative disorders. T cells are not affected. This makes acadesine and its bioprecursors (e.g., its mono-, di- and tri-5'-phosphates) can be converted into therapeutic agents useful for lymphoproliferative disorders in humans. The surprising feature that T cells are virtually not affected means that the harmful secondary effect (immunosuppression) is minor, what represents a therapeutical advantage of acadesine over cladribine, fludarabine and other nucleosides known in the art.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The present invention relates to a cosmetic composition for excellent skin moisturizing effect, skin whitening effect, and skin wrinkle reducing effect by containing a nanoemulsion extract consisting of Dioscorea japonica Thunb., Aloe vera (L.) Burm. f., Daucus carota sub sp. sativa (Hoffm.) Arcang., Pinus densiflora Siebold et Zucc. leaves, and Eulota Peliophala Pfr. and, more specifically, to a cosmetic composition having excellent skin moisturizing effect, skin whitening effect, and skin wrinkle reducing effect, and containing an extract obtained by nanoemulsion extraction of Dioscorea japonica Thunb., Aloe vera (L.) Burm. f., Daucus carota sub sp. sativa (Hoffm.) Arcang., Pinus densiflora Siebold et Zucc. leaves, and Eulota Peliophala Pfr. as main ingredients.
INTRODUCTION: Malignant non-melanoma skin cancers (NMSC) are of two main types: basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). In rare occasions, some of the malignant skin lesions show histopathological characteristics of both BCC and SCC and are known as basosquamous carcinomas (BSC). In some cases of large tumors, extensive reconstructive surgery might be needed to correct the skin defect after the primary excision.
PRESENTATION OF CASE: We report a case of a 76-year-old Bulgarian male patient who presented with a neglected giant cutaneous tumor with more than a 15-year history of a growing mass in the right deltoid area. On physical exam an enormous exophytic ulcerated and crusted skin lesion measuring around 11×11cm was found. Wide local excision of the lesion with 10-mm resection margins and partial resection of the underlying deltoid muscle were performed due to signs of infiltration. A full-thickness total skin graft from the left inguinal area was harvested to cover the skin defect. Final histopathological examination showed metatypical carcinoma with mixed characteristics of SCC and BCC - BSC, with infiltration of the fatty tissue, deltoid muscle and clear margins of resection, staged as T4R0. Two and a half years after surgery there are no signs of upper arm motor dysfunction and no evidence of local recurrence and distant metastasis on a follow-up PET/CT.
DISCUSSION: Following current National Comprehensive Cancer Network's guidelines for primary treatment of BCC, surgical candidates should undergo standard excision with wider surgical margins, postoperative margin assessment and second intention healing, linear repair, or skin graft. Therapeutic strategy for non-operable cases includes administration of radiotherapy or system therapy in the face of Hedgehog pathway inhibitors and programmed cell death protein 1 inhibitor. They can provide an alternative solution to unresectable or difficult-to-treat locally advanced cases of BSC.
CONCLUSION: Similarly to BCC and SCC, the first-line treatment option for BCS is surgical excision, but surgical margins should be wider than those for low-risk BCC due to the infiltrative growth pattern of this tumor. Favorable esthetic outcome requires precise planning of the reconstructive technique.
PBSC will be intravenously infused at a dose of 2×10\^8/kg. MSCs will be intravenously infused at a dose of 1×10\^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given.
BACKGROUND: Hip osteoarthritis (OA) is a leading cause of chronic pain and disability worldwide. Self-management is vital with education, exercise and weight loss core recommended treatments. However, evidence-practice gaps exist, and service models that increase patient accessibility to clinicians who can support lifestyle management are needed. The primary aim of this study is to determine the effectiveness of a telehealth-delivered clinician-supported exercise and weight loss program (Better Hip) on the primary outcomes of hip pain on walking and physical function at 6 months, compared with an information-only control for people with hip OA.
METHODS: A two-arm, parallel-design, superiority pragmatic randomised controlled trial. 212 members from a health insurance fund aged 45 years and over, with painful hip OA will be recruited. Participants will be randomly allocated to receive: i) Better Hip; or ii) web-based information only (control). Participants randomised to the Better Hip program will have six videoconferencing physiotherapist consultations for education about OA, prescription of individualised home-based strengthening and physical activity programs, behaviour change support, and facilitation of other self-management strategies. Those with a body mass index > 27 kg/m2, aged < 80 years and no specific health conditions, will also be offered six videoconferencing dietitian consultations to undertake a weight loss program. Participants in the control group will be provided with similar educational information about managing hip OA via a custom website. All participants will be reassessed at 6 and 12 months. Primary outcomes are hip pain on walking and physical function. Secondary outcomes include measures of pain; hip function; weight; health-related quality of life; physical activity levels; global change in hip problem; willingness to undergo hip replacement surgery; rates of hip replacement; and use of oral pain medications. A health economic evaluation at 12 months will be conducted and reported separately.
DISCUSSION: Findings will determine whether a telehealth-delivered clinician-supported lifestyle management program including education, exercise/physical activity and, for those with overweight or obesity, weight loss, is more effective than information only in people with hip OA. Results will inform the implementation of such programs to increase access to core recommended treatments.
TRIAL REGISTRATION: Australia New Zealand Clinical Trials Registry (ACTRN12622000461796).
OBJECTIVES: I. Compare gemcitabine plus vinorelbine vs standard chemotherapy containing cisplatin in terms of the effect on the quality of life of patients with stage IIIB or IV non-small cell lung cancer. II. Compare the effect of these regimens on the overall survival of these patients. III. Compare the toxic effects of these regimens in these patients. IV. Compare the effect of these regimens on the rate of objective response in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, stage of disease (IIIB vs IV), and performance status (0 vs 1 vs 2). Patients are randomized to one of two treatment arms. Arm I: Patients receive cisplatin IV on day 1 and either gemcitabine IV or vinorelbine IV on days 1 and 8. Arm II: Patients receive gemcitabine IV and vinorelbine IV on days 1 and 8. Treatment repeats every 21 days for up to 6 courses. Quality of life is assessed prior to therapy and before each course of chemotherapy to the fourth course.

PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.
The invention develops and discloses a construction method and application of a cervical cancer methylation related long-chain non-coding RNA prognosis and immunotherapy curative effect prediction model. RNA methylation-associated lncRNAs were screened using Pearson correlation algorithm. And constructing a prognosis model of the cervical cancer RNA methylation related IncRNA by single-factor and multi-factor regression analysis. Drawing ROC and Kaplan-Meier survival curves, constructing a Nomo model, drawing a calization graph, and performing independent prognosis analysis to evaluate the accuracy of the model. And evaluating the correlation between the risk model and clinical characteristics, immune cell infiltration, tumor Mutation Burden (TMB), immune function and immune therapy related molecules. Finally, an online database is used for evaluating prognosis and immunotherapy value of methylation key lncRNAs, and IC50 is calculated to predict the effectiveness of the novel drug based on the target risk model. In short, the prognosis and immunotherapy efficacy prediction model can be used for guiding prognosis and making personalized treatment strategies, and cervical cancer diagnosis and prognosis related products can be further developed according to key molecules in the prognosis model.
Papaverine given as an intracavernosal injection is used in the treatment of impotence. It is today injected in form of papaverine sulphate or papaverine hydrochloride. This has very serious complications because of the high acidity and the high concentration of papaverine, H+. It gives fibrosis of the corpus cavernosum penis, pain, scarring and induration. It is shown that a semistable or fell out solution of papaverine can be created by the addition of a base, with the same therapeutical effect as to the quality and duration of erection and without the above mentioned complications thus being a significant improvement in the treatment of impotence. To inject the above mentioned mixture there is developed a single unit two compartment injecting/mixing device. The two solutions in compartment x and y are separated by a disc (B). The disc (B) is held in place by the tension of the wall (A) but can easily be brought to a perpendicular position thus allowing the solutions to mix. The main advantage of the system is the smooth interior sufaces to create controlled microcrystalline fell out and, as it is a closed system, the non risk of contamination.
COHORT I: Patients receive NBTXR3 intratumorally on day 1. Patients also receive ( anti-PD-1/L-1) intravenously (IV) on day 8. Beginning day 15, patients undergo Abscopal radiation therapy over 1-2 weeks. Cycles with ( anti-PD-1/L-1) repeat every 3-6 weeks per standard of care up to 2 years in the absence of disease progression or unacceptable toxicity.
Spinocerebellar ataxia type 12 is a hereditary and neurodegenerative illness commonly found in India. However, there is no established noninvasive automatic diagnostic system for its diagnosis and identification of imaging biomarkers. This work proposes a novel four-phase machine learning-based diagnostic framework to find spinocerebellar ataxia type 12 disease-specific atrophic-brain regions and distinguish spinocerebellar ataxia type 12 from healthy using a real structural magnetic resonance imaging dataset. Firstly, each brain region is represented in terms of statistics of coefficients obtained using 3D-discrete wavelet transform. Secondly, a set of relevant regions are selected using a graph network-based method. Thirdly, a kernel support vector machine is used to capture nonlinear relationships among the voxels of a brain region. Finally, the linear relationship among the brain regions is captured to build a decision model to distinguish spinocerebellar ataxia type 12 from healthy by using the regularized logistic regression method. A classification accuracy of 95% and a harmonic mean of precision and recall, i.e. F1-score of 94.92%, is achieved. The proposed framework provides relevant regions responsible for the atrophy. The importance of each region is captured using Shapley Additive exPlanations values. We also performed a statistical analysis to find volumetric changes in spinocerebellar ataxia type 12 group compared to healthy. The promising result of the proposed framework shows that clinicians can use it for early and timely diagnosis of spinocerebellar ataxia type 12.
Players with a recent (\<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.
A process for the manufacture of an influenza vaccine comprises cultivating an influenza virus, pathogenic towards the epithelium of the respiratory tract of a mammal, in the pulmonary tissue of a mammal until its pathogenicity towards said epithelium is not modified by being passed through an incubated fertile hen's egg, then allowing a resulting virus to multiply in an incubated fertile hen's egg and preparing the vaccine from the virus-containing allantoic liquid so obtained, and, if desired, adding an adjuvant.  The vaccine may be inactivated by formaldehyde, hydroxylamine, b -propiolactam or ultra-violet radiation.  The adjuvant may be alum, aluminium phosphate or hydroxide, or incomplete Freund's adjuvant.  Influenza virus types A, B and C and their strains, e.g. A/PR8, A1/FM1, A1/Ann Arbor, A2/Asia, A2/Japan, B\Stockholm, B/Johannesburg, B/Maryland, B/Lee or C/Taylor may be used.  An example describes influenza vaccines comprising influenza viruses of the A2/Asia strain Singapore cultivated by means of 424 passages through pulmonary tissue of mice and subsequently 33 passages through incubated eggs.
The burden of chronic metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction-associated steatotic liver disease (MASLD) and the urgency of the epidemiological situation necessitate the development of therapies that enhance metabolic health and alter the trajectory of metabolic disease in society. Certain bariatric-metabolic surgeries have proven to be effective approaches for treating metabolic dysfunction, showing remission or significant improvements in obesity, T2DM, and MASLD-related outcomes, suggesting that these interventions might be able to "reset" a pathologically calibrated metabolic setpoint. However, considering the challenges and invasiveness of surgery, endoscopic bariatric metabolic therapies (EBMTs) have emerged with a primary focus to reconstruct or mimic anatomical and/or functional changes observed with bariatric surgery in a more broadly accessible manner. These innovative approaches offer a potentially promising solution to address significant unmet medical need in the large segment of society, which remains at risk for the consequences of metabolic diseases. In this review, we discuss therapeutic options within the EBMT space in the context of the metabolic setpoint intellectual model and provide a brief overview of current knowledge surrounding their mechanisms of action and impact on metabolic health. Finally, we explore future perspectives and directions in this exciting field.
Allergic broncho-pulmonary aspergillosis (ABPA) is not rare in the context of cystic fibrosis (CF), with a prevalence reported between 2% to 16%. This complication is a diagnostic challenge for clinicians, since it is related with poorer outcome and higher worsening of the disease. Therefore, the treatment relies on corticosteroid and antifungal therapy and thus, it is important to detect with good sensitivity because CF patients are usually treated with antibiotics. However, the treatment is often difficult to be initiated because of potential secondary side effects related to diabetes mellitus, growth impairment, bone mineralisation or immunodepression. Therefore, there is a need for specific diagnostic tool to discriminate ABPA amongst other polymicrobial infection.

Lung MRI is a radiation-free imaging modality which offers the potential to combine several contrasts, in order to enable in vivo tissue characterization non-invasively. Investigators hypothesize that characterization of mucoid impaction using lung MR T1-weighted and T2-weighted contrasts may be a specific tool to diagnose ABPA in CF non invasively. Additional information on functional information related to ventilation and/or perfusion will be assessed using functional MR sequences, to assess the severity of small airway impairment. Moreover, the diagnostic value of structural alterations such as bronchiectasis, mucoid impaction and consolidation/atelectasis using either MRI with ultrashort echo times or CT using reduction of doses down to chest radiograph levels will be assessed.